8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 20, 2026·SEC
Prelude Therapeutics Incorporated(PRLD)Earnings, Financials & Key Ratios
PRLD•NASDAQ
Price updated Jun 19, 2026
AboutPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.Show more
- Revenue$12M+73.4%
- EBITDA-$103M+25.4%
- Net Income-$99M+21.8%
- EPS (Diluted)-1.29+23.2%
- Gross Margin85.91%-14.1%
- EBITDA Margin-847.24%+57.0%
- Operating Margin-861.33%+56.8%
- Net Margin-819.59%+54.9%
- ROE-99.45%-44.1%
PRLD Key Insights
Prelude Therapeutics Incorporated (PRLD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Profits declining 11.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PRLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRLD Price & Volume
Prelude Therapeutics Incorporated (PRLD) stock price & volume — 10-year historical chart
Loading chart...
PRLD Growth Metrics
Prelude Therapeutics Incorporated (PRLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM138.86%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM37.28%
Return on Capital
10 Years-81.43%
5 Years-62.3%
3 Years-71.62%
Last Year-87.8%
PRLD Recent Earnings
Prelude Therapeutics Incorporated (PRLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.13+51.9%
$0.27
Rev
$5M+0.0%
$5M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.20+39.4%
$0.33
Rev
$6M-72.7%
$21M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.26+25.7%
$0.35
Rev
$7M-68.3%
$21M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.41+8.9%
$0.45
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.13vs $0.27+51.9% | $5Mvs $5M+0.0% |
| Q2 2026 | Mar 10, 2026 | $0.20vs $0.33+39.4% | $6Mvs $21M-72.7% |
| Q4 2025 | Nov 12, 2025 | $0.26vs $0.35+25.7% | $7Mvs $21M-68.3% |
| Q3 2025 | Aug 14, 2025 | $0.41vs $0.45+8.9% | — |
Based on last 12 quarters of dataView full earnings history →
PRLD Peer Comparison
Prelude Therapeutics Incorporated (PRLD) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% |
Compare PRLD vs Peers
Prelude Therapeutics Incorporated (PRLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRLD Income Statement
Prelude Therapeutics Incorporated (PRLD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 12.14M | 16.72M |
Revenue Growth % | - | - | - | - | - | - | - | 73.43% | 138.86% |
Cost of Goods Sold | 149K | 0 | 0 | 0 | 0 | 0 | 0 | 1.71M | 391K |
COGS % of Revenue | - | - | - | - | - | - | - | 14.09% | - |
Gross Profit | -149K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 7M▲ 0% | 10.43M▲ 49.0% | 16.33M▲ 0% |
Gross Margin % | - | - | - | - | - | - | 100% | 85.91% | 97.66% |
Gross Profit Growth % | - | 100% | - | - | - | - | - | 48.99% | - |
Operating Expenses | 14.97M | 28.11M | 58.76M | 113.73M | 123.54M | 132.28M | 146.71M | 115M | 100.47M |
OpEx % of Revenue | - | - | - | - | - | - | 2095.91% | 947.24% | - |
Selling, General & Admin | 2.35M | 3.83M | 10.59M | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M | 21.38M |
SG&A % of Revenue | - | - | - | - | - | - | 410.27% | 184.56% | - |
Research & Development | 12.62M | 24.28M | 48.18M | 86.78M | 92.89M | 103.39M | 118M | 94.3M | 79.08M |
R&D % of Revenue | - | - | - | - | - | - | 1685.64% | 776.77% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1.71M | 0 |
Operating Income | -14.97M▲ 0% | -28.11M▼ 87.7% | -58.76M▼ 109.1% | -113.73M▼ 93.5% | -123.54M▼ 8.6% | -132.28M▼ 7.1% | -139.71M▼ 5.6% | -104.57M▲ 25.2% | -84.14M▲ 0% |
Operating Margin % | - | - | - | - | - | - | -1995.91% | -861.33% | -503.21% |
Operating Income Growth % | - | -87.71% | -109.05% | -93.55% | -8.62% | -7.07% | -5.62% | 25.16% | - |
EBITDA | -14.83M | -27.73M | -58.22M | -112.82M | -122.22M | -131.11M | -137.94M | -102.86M | -82.47M |
EBITDA Margin % | - | - | - | - | - | - | -1970.6% | -847.24% | -493.24% |
EBITDA Growth % | - | -87.02% | -109.98% | -93.78% | -8.33% | -7.28% | -5.21% | 25.44% | 40.32% |
D&A (Non-Cash Add-back) | 149K | 382K | 542K | 915K | 1.32M | 1.17M | 1.77M | 1.71M | 1.67M |
EBIT | -14.97M | -28.11M | -58.76M | -113.73M | -123.54M | -132.28M | -139.71M | -104.57M | -84.14M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 295K | 539K | 1.83M | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M | 6.34M |
Pretax Income | -14.68M▲ 0% | -27.57M▼ 87.8% | -56.93M▼ 106.5% | -111.69M▼ 96.2% | -115.44M▼ 3.4% | -121.83M▼ 5.5% | -127.17M▼ 4.4% | -99.5M▲ 21.8% | -77.8M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | -1816.76% | -819.59% | -465.3% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -14.68M▲ 0% | -27.57M▼ 87.8% | -56.93M▼ 106.5% | -111.69M▼ 96.2% | -115.44M▼ 3.4% | -121.83M▼ 5.5% | -127.17M▼ 4.4% | -99.5M▲ 21.8% | -77.8M▲ 0% |
Net Margin % | - | - | - | - | - | - | -1816.76% | -819.59% | -465.3% |
Net Income Growth % | - | -87.81% | -106.49% | -96.2% | -3.35% | -5.54% | -4.38% | 21.76% | 39.14% |
Net Income (Continuing) | -14.68M | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.5M | -77.8M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -9.31▲ 0% | -0.85▲ 90.9% | -1.30▼ 52.9% | -2.33▼ 79.2% | -2.27▲ 2.6% | -2.02▲ 11.0% | -1.68▲ 16.8% | -1.29▲ 23.2% | -0.94▲ 0% |
EPS Growth % | - | 90.87% | -52.94% | -79.23% | 2.58% | 11.01% | 16.83% | 23.21% | 37.28% |
EPS (Basic) | -9.31 | -0.85 | -1.30 | -2.33 | -2.27 | -2.02 | -1.68 | -1.29 | - |
Diluted Shares Outstanding | 1.58M | 32.4M | 43.71M | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M | 82.52M |
Basic Shares Outstanding | 1.58M | 32.4M | 43.71M | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M | 82.52M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PRLD Balance Sheet
Prelude Therapeutics Incorporated (PRLD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.6M | 20.22M | 220.81M | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M | 84.59M |
Cash & Short-Term Investments | 15.6M | 18.88M | 218.31M | 291.23M | 201.73M | 232.94M | 133.61M | 103.21M | 81.55M |
Cash Only | 15.6M | 18.88M | 218.31M | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M | 21.76M |
Short-Term Investments | 0 | 0 | 0 | 259.4M | 171.12M | 207.64M | 121.14M | 67.96M | 59.8M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.5M | 0 | 2.65M | 2.65M | 2.28M | 2.48M | 3.04M |
Total Non-Current Assets | 811K | 1.65M | 2.78M | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M | 35.05M |
Property, Plant & Equipment | 811K | 1.65M | 2.48M | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M | 31.5M |
Fixed Asset Turnover | - | - | - | - | - | - | 0.20x | 0.38x | 0.51x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.23M |
Other Non-Current Assets | 0 | 0 | 301K | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M | 3.55M |
Total Assets | 16.41M▲ 0% | 21.87M▲ 33.3% | 223.59M▲ 922.3% | 305.1M▲ 36.5% | 220.5M▼ 27.7% | 277.67M▲ 25.9% | 175.51M▼ 36.8% | 141.31M▼ 19.5% | 119.64M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.04x | 0.09x | 0.14x |
Asset Growth % | - | 33.31% | 922.31% | 36.45% | -27.73% | 25.93% | -36.79% | -19.49% | -135.51% |
Total Current Liabilities | 2.45M | 4.83M | 11.38M | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M | 41.72M |
Accounts Payable | 1.36M | 1.97M | 3.92M | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M | 2.07M |
Days Payables Outstanding | 3.34K | - | - | - | - | - | - | 849.68 | 3.16K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.74M | 2.76M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.73M | 64.69M |
Other Current Liabilities | 0 | 1.63M | 420K | 5.01M | 6.21M | 6.61M | 9.79M | 12.53M | 5.94M |
Current Ratio | 6.37x | 4.18x | 19.41x | 15.37x | 9.42x | 10.79x | 5.30x | 1.99x | 2.03x |
Quick Ratio | 6.37x | 4.18x | 19.41x | 15.37x | 9.42x | 10.79x | 5.30x | 1.99x | 2.03x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 36.65M | 66.45M | 32K | 0 | 3.36M | 18.75M | 18.41M | 19.68M | 17.74M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.04M | 14.96M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 15.41M | 15.32M | 0 | 45.38M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 36.65M | 66.45M | 32K | 0 | 3.36M | 3.34M | 3.09M | 4.64M | 2.78M |
Total Liabilities | 39.1M | 71.28M | 11.41M | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M | 59.46M |
Total Debt | 0 | 258K | 0 | 1.74M | 1.83M | 16.89M | 18.02M | 17.79M | 17.72M |
Net Debt | -15.6M | -18.62M | -218.31M | -30.09M | -28.77M | -8.4M | 5.55M | -17.47M | -4.04M |
Debt / Equity | - | - | - | 0.01x | 0.01x | 0.07x | 0.14x | 0.26x | 0.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.21x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.05x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -22.69M▲ 0% | -49.41M▼ 117.7% | 212.18M▲ 529.4% | 285.9M▲ 34.7% | 195.44M▼ 31.6% | 237.09M▲ 21.3% | 131.46M▼ 44.6% | 68.64M▼ 47.8% | 60.18M▲ 0% |
Equity Growth % | - | -117.74% | 529.42% | 34.74% | -31.64% | 21.31% | -44.55% | -47.79% | -210.43% |
Book Value per Share | -14.40 | -1.52 | 4.85 | 6.01 | 4.13 | 3.93 | 1.73 | 0.89 | 0.73 |
Total Shareholders' Equity | -22.69M | -49.41M | 212.18M | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M | 60.18M |
Common Stock | 0 | 0 | 4K | 5K | 5K | 5K | 5K | 5K | 5K |
Retained Earnings | -22.93M | -50.5M | -107.43M | -219.12M | -334.56M | -456.39M | -583.56M | -683.06M | -693.45M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -191K | 0 | -223.59M | -711K | -1.69M | 223K | 35K | 8K | -41K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRLD Cash Flow Statement
Prelude Therapeutics Incorporated (PRLD) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.95M | -25.66M | -46.18M | -83.53M | -83.73M | -107.06M | -102.89M | -56.3M | -43.76M |
Operating CF Margin % | - | - | - | - | - | - | -1469.83% | -463.77% | - |
Operating CF Growth % | - | -98.12% | -79.92% | -80.89% | -0.24% | -27.87% | 3.9% | 45.28% | 264.98% |
Net Income | -14.68M | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.5M | -77.8M |
Depreciation & Amortization | 149K | 382K | 542K | 915K | 1.32M | 1.17M | 1.77M | 1.34M | 1.53M |
Stock-Based Compensation | 180K | 846K | 5.58M | 20.93M | 25.14M | 25.62M | 21.34M | 11.91M | 8.08M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 15K | 10K | 11K | 2.69M | 4.31M | -1.54M | -3.05M | 1.53M | 2.83M |
Working Capital Changes | 1.38M | 667K | 4.62M | 3.63M | 932K | -10.48M | 4.22M | 28.41M | 21.59M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 721K | 546K | 1.16M | 3.9M | -347K | -2.27M | 3.31M | -3.92M | -3.89M |
Cash from Investing | -529K | -780K | -621K | -263.8M | 81.69M | -34.65M | 90.19M | 53.46M | -228K |
Capital Expenditures | -529K | -780K | -621K | -2.32M | -3.02M | -3.51M | -764K | -67K | -20K |
CapEx % of Revenue | - | - | - | - | - | - | 10.91% | 0.55% | 0.12% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 17.94M | 29.73M | 246.23M | 164.9M | 815K | 136.4M | -120K | 24.82M | 24.66M |
Debt Issued (Net) | 0 | -124K | -258K | 0 | 0 | 0 | -395K | -208K | -53K |
Equity Issued (Net) | 17.94M | 29.85M | 246.4M | 161.42M | 0 | 135.73M | 329K | 25.04M | 24.78M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 5K | 88K | 3.47M | 815K | 664K | -54K | -17K | -63K |
Net Change in Cash | 4.45M▲ 0% | 3.28M▼ 26.3% | 199.43M▲ 5972.8% | -182.44M▼ 191.5% | -1.22M▲ 99.3% | -5.31M▼ 334.5% | -12.82M▼ 141.2% | 21.97M▲ 271.4% | -19.32M▲ 0% |
Free Cash Flow | -13.48M▲ 0% | -26.45M▼ 96.1% | -46.8M▼ 77.0% | -85.85M▼ 83.5% | -86.75M▼ 1.0% | -110.58M▼ 27.5% | -103.65M▲ 6.3% | -56.37M▲ 45.6% | -43.78M▲ 0% |
FCF Margin % | - | - | - | - | - | - | -1480.74% | -464.32% | -261.82% |
FCF Growth % | - | -96.14% | -76.96% | -83.46% | -1.04% | -27.47% | 6.26% | 45.62% | 58.64% |
FCF per Share | -8.55 | -0.82 | -1.07 | -1.80 | -1.83 | -1.83 | -1.37 | -0.73 | -0.53 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.93x | 0.81x | 0.75x | 0.73x | 0.88x | 0.81x | 0.57x | 0.56x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRLD Key Ratios
Prelude Therapeutics Incorporated (PRLD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -69.95% | -44.85% | -47.97% | -56.34% | -69.01% | -99.45% | -118.24% |
Return on Invested Capital (ROIC) | - | - | -68.33% | -43.86% | -50.19% | -57.31% | -83.35% | -123.62% |
Gross Margin | - | - | - | - | - | 100% | 85.91% | 97.66% |
Net Margin | - | - | - | - | - | -1816.76% | -819.59% | -465.3% |
Debt / Equity | - | - | 0.01x | 0.01x | 0.07x | 0.14x | 0.26x | 0.29x |
FCF Conversion | 0.93x | 0.81x | 0.75x | 0.73x | 0.88x | 0.81x | 0.57x | 0.56x |
Revenue Growth | - | - | - | - | - | - | 73.43% | 138.86% |
Related:PRLD Dividend History·PRLD Revenue History·PRLD Price History·PRLD P/E History·PRLD Financial Ratios·PRLD Institutional Holders
PRLD SEC Filings & Documents
Prelude Therapeutics Incorporated (PRLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRLD Frequently Asked Questions
Prelude Therapeutics Incorporated (PRLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prelude Therapeutics Incorporated (PRLD) reported $16.7M in revenue for fiscal year 2025.
Prelude Therapeutics Incorporated (PRLD) grew revenue by 73.4% over the past year. This is strong growth.
Prelude Therapeutics Incorporated (PRLD) reported a net loss of $77.8M for fiscal year 2025.
Dividend & Returns
Prelude Therapeutics Incorporated (PRLD) has a return on equity (ROE) of -99.5%. Negative ROE indicates the company is unprofitable.
Prelude Therapeutics Incorporated (PRLD) had negative free cash flow of $43.8M in fiscal year 2025, likely due to heavy capital investments.